S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
pixel
pixel
NASDAQ:ANIK

Anika Therapeutics Stock Forecast, Price & News

$39.62
+0.21 (+0.53 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.95
$39.94
50-Day Range
$38.75
$43.30
52-Week Range
$32.04
$48.37
Volume34,124 shs
Average Volume110,085 shs
Market Capitalization$571.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24
30 days | 90 days | 365 days | Advanced Chart
Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Anika Therapeutics logo

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

190th out of 1,351 stocks

Surgical & Medical Instruments Industry

23rd out of 123 stocks

Analyst Opinion: 2.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

Is Anika Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Anika Therapeutics stock.
View analyst ratings for Anika Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Anika Therapeutics?

Wall Street analysts have given Anika Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Anika Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Anika Therapeutics
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings results on Wednesday, August, 4th. The biotechnology company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.60. The biotechnology company had revenue of $38.15 million for the quarter, compared to the consensus estimate of $34.51 million. Anika Therapeutics had a negative net margin of 9.28% and a negative trailing twelve-month return on equity of 0.93%.
View Anika Therapeutics' earnings history
.

How has Anika Therapeutics' stock price been impacted by Coronavirus?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANIK shares have increased by 8.9% and is now trading at $39.62.
View which stocks have been most impacted by COVID-19
.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $144.81 million-$148.72 million, compared to the consensus revenue estimate of $144.15 million.

What price target have analysts set for ANIK?

2 Wall Street analysts have issued 1-year target prices for Anika Therapeutics' shares. Their forecasts range from $43.00 to $46.00. On average, they expect Anika Therapeutics' share price to reach $44.50 in the next twelve months. This suggests a possible upside of 12.3% from the stock's current price.
View analysts' price targets for Anika Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Cheryl R. Blanchard, President, Chief Executive Officer & Director
  • Michael L. Levitz, Chief Financial Officer, Treasurer & EVP (LinkedIn Profile)
  • Mira Leiwant, VP-Quality, Regulatory & Clinical Affairs
  • Steven W. Ek, Vice President-Research & Development
  • David Colleran, Secretary, Executive VP & General Counsel

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.37%), Kayne Anderson Rudnick Investment Management LLC (10.05%), Vanguard Group Inc. (6.64%), State Street Corp (6.23%), Dimensional Fund Advisors LP (5.92%) and Renaissance Technologies LLC (4.98%). Company insiders that own Anika Therapeutics stock include James Loerop, John B Henneman III, Michael L Levitz, Michael L Levitz, Michael L Levitz, Raymond J Land and Sylvia Cheung.
View institutional ownership trends for Anika Therapeutics
.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Morgan Stanley, Morgan Stanley, Millennium Management LLC, Capital Management Corp VA, State Street Corp, Renaissance Technologies LLC, and Bank of America Corp DE.
View insider buying and selling activity for Anika Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Trigran Investments Inc., Fort Washington Investment Advisors Inc. OH, Vanguard Group Inc., Nuveen Asset Management LLC, GSA Capital Partners LLP, Northern Trust Corp, and Jackson Creek Investment Advisors LLC. Company insiders that have bought Anika Therapeutics stock in the last two years include John B Henneman III, and Michael L Levitz.
View insider buying and selling activity for Anika Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $39.62.

How much money does Anika Therapeutics make?

Anika Therapeutics has a market capitalization of $571.44 million and generates $130.46 million in revenue each year. The biotechnology company earns $-23,980,000.00 in net income (profit) each year or $0.71 on an earnings per share basis.

How many employees does Anika Therapeutics have?

Anika Therapeutics employs 277 workers across the globe.

When was Anika Therapeutics founded?

Anika Therapeutics was founded in 1992.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is www.anikatherapeutics.com.

Where are Anika Therapeutics' headquarters?

Anika Therapeutics is headquartered at 32 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at (781) 457-9000 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.